Joseph Catanzaro
Stock Analyst at Mizuho
(3.43)
# 965
Out of 5,090 analysts
97
Total ratings
45%
Success rate
6.39%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Initiates: Outperform | $24 | $18.09 | +32.67% | 3 | Oct 21, 2025 | |
| RVMD Revolution Medicines | Initiates: Outperform | $90 | $79.64 | +13.01% | 3 | Oct 21, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | $48 | $29.45 | +62.99% | 1 | Oct 21, 2025 | |
| APGE Apogee Therapeutics | Initiates: Outperform | $105 | $76.75 | +36.81% | 1 | Oct 21, 2025 | |
| KYMR Kymera Therapeutics | Initiates: Outperform | $81 | $66.62 | +21.59% | 1 | Oct 21, 2025 | |
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.29 | +118.34% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $3.95 | +26.58% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.20 | +172.73% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $17.64 | +155.10% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $96.14 | -12.63% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $121.22 | -9.26% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $44.36 | -14.34% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $21.69 | -30.84% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $63.33 | -16.31% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $2.11 | +373.93% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.22 | +1,457.38% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $10.18 | +86.64% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.67 | +461.80% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $26.72 | +34.73% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $7.92 | +405.05% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.58 | +19.24% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.05 | +328.57% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $2.37 | +1,165.82% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.14 | +1,654.39% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $9.63 | +86.92% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $2.22 | +1,028.67% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $5.46 | -67.95% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $23.53 | -15.00% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.40 | -37.50% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $9.72 | +1,957.61% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.43 | +206.21% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.32 | +4,445.45% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.48 | +625.81% | 3 | Apr 7, 2020 |
Nurix Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $24
Current: $18.09
Upside: +32.67%
Revolution Medicines
Oct 21, 2025
Initiates: Outperform
Price Target: $90
Current: $79.64
Upside: +13.01%
Celldex Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $29.45
Upside: +62.99%
Apogee Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $76.75
Upside: +36.81%
Kymera Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $81
Current: $66.62
Upside: +21.59%
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.29
Upside: +118.34%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $3.95
Upside: +26.58%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.20
Upside: +172.73%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $17.64
Upside: +155.10%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $96.14
Upside: -12.63%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $121.22
Upside: -9.26%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $44.36
Upside: -14.34%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $21.69
Upside: -30.84%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $63.33
Upside: -16.31%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.11
Upside: +373.93%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.22
Upside: +1,457.38%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $10.18
Upside: +86.64%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.67
Upside: +461.80%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $26.72
Upside: +34.73%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $7.92
Upside: +405.05%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $12.58
Upside: +19.24%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.05
Upside: +328.57%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $2.37
Upside: +1,165.82%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.14
Upside: +1,654.39%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $9.63
Upside: +86.92%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $2.22
Upside: +1,028.67%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $5.46
Upside: -67.95%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $23.53
Upside: -15.00%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.40
Upside: -37.50%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $9.72
Upside: +1,957.61%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $11.43
Upside: +206.21%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.32
Upside: +4,445.45%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.48
Upside: +625.81%